Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today highlighted recent scientific ...
Immuneering Corporation is developing novel small molecules for cyclical inhibition of MEK targets, but they are still in early development. Their first developmental project, IMM-1-104, has shown ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results